Tag: Israel
-
Drug Delivery Biotech Raises $101.8 Million in IPO
17 July 2015. Chiasma Inc., a biotechnology enterprise developing oral therapies to replace injected drugs, raised some $101.8 million in its initial public stock offering. The company — located in Newton, Massachusetts and Jerusalem, Israel — issued 6,365,000 shares at $16.00, and trades on the Nasdaq exchange under the symbol CHMA. Shares in the company closed…
-
Stem Cells Treat Vision Disorders in Animal Tests
4 May 2015. Tests with lab rats of a therapy for degenerating retinas in the eyes, show the treatments derived from human embryonic stem cells can restore visual functions. Results of the treatments, developed by Cell Cure Neurosciences Ltd., are scheduled to be reported today by a research team from Oregon Health and Science University…
-
Device Shown to Reduce Stroke in Heart Valve Replacements
16 March 2015. First results from a clinical trial in Europe and Israel show an experimental mesh device deployed during heart valve replacement surgery sharply reduces strokes and cognitive damage, complications associated with the procedure. A team from Yale University School of Medicine presented its findings yesterday of the study testing TriGuard, made by Keystone…
-
Stem Cells Shown Effective with Autism in Lab
26 January 2015. The biotechnology company BrainStorm Cell Therapeutics Inc. reports that tests in laboratory mice show its stem cell technology derived from bone marrow is effective in reducing behaviors associated with autism. The study was conducted by Daniel Offen, a neuroscientist at Tel Aviv University in Israel, but no peer-reviewed publication was cited by…
-
Pump Device Shown to Deliver Parkinson’s Drug
30 December 2014. A clinical trial testing a pump worn by Parkinson’s disease patients shows the device can continuously deliver drugs under the skin to treat severe forms of the disorder, which today requires a surgical implant. The pump made by NeuroDerm Ltd. in Rehovot, Israel is designed to overcome shortcomings of oral forms of…
-
Pfizer, Opko Partner on Growth Hormone Drug
16 December 2014. The pharmaceutical company Pfizer is licensing an engineered compound to treat human growth hormone deficiency in adults and children from Opko Health Inc., a provider of therapeutics and diagnostics. The deal has a potential value to Opko of $570 million, plus royalties from sales. Opko Health, based in Miami, offers drugs and…
-
Drug-Error Analytics Service Raises $1M in Early Funding
2 October 2014. MedAware, a company harnessing big-data analytics to prevent erroneous drug prescriptions, raised $1 million in its first round of venture financing. The Ra’anana, Israel enterprise completed the funding round led by OurCrowd, an Israeli crowdfunding investment service, with contributions from GE Ventures. The company is the creation of CEO Gidi Stein, a…
-
Gold Nanoparticles Boost Heart Tissue Patch Performance
1 October 2014. Medical and materials scientists at Tel Aviv University in Israel designed a heart tissue repair patch that adds in gold nanoparticles to improve electrical signaling and muscle performance. The team from the lab of life sciences professor Tal Dvir published its findings last month in the journal Nano Letters (paid subscription required).…
-
Implant Developed to Measure Pressure Causing Glaucoma
26 August 2014. Biomedical engineers at Stanford University in California and Bar-Ilan University in Israel designed an implanted device for people with glaucoma to take frequent and accurate measures of high pressure inside their eyes, a factor closely associated with glaucoma. The team led by Stanford bioengineering professor Stephen Quake and Bar-Ilan ophthalmologist Yossi Mandel…
-
Novartis Acquires Stake in Stem Cell Therapy Company
19 August 2014. Gamida Cell, a developer of therapies from umbilical cord stem cells, says the global pharmaceutical company Novartis is buying a 15 percent interest in the company, with an option to acquire the entire company later. The deal brings Gamida Cell, located in Jerusalem, Israel, $35 million immediately, with a total potential return…